Literature DB >> 21873624

Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease.

Bjarne Orskov1, Vibeke Rømming Sørensen, Bo Feldt-Rasmussen, Svend Strandgaard.   

Abstract

BACKGROUND: With the improved prognosis in patients with autosomal dominant polycystic kidney disease (ADPKD), causes of death and the risk of cancer might have changed. This was investigated in a Danish population with ADPKD and end-stage renal disease (ESRD) between 1 January 1993 and 31 December 2008.
METHODS: Data were retrieved from three Danish national registries and a total of 823 patients were identified of which 431 had died during the study period. The 16 years were divided into two 8-year periods and the causes of death were divided into six categories: cancer, cardiovascular, cerebrovascular, infection, other and unknown.
RESULTS: Cardiovascular disease was the major cause of death. A multivariate competing risk model comparing the two 8-year periods, adjusted for age at ESRD, gender and treatment modality, showed that deaths from cardiovascular disease decreased by 35% [hazard ratios (HR) 0.65, P=0.008] and deaths from cerebrovascular disease decreased by 69% (HR 0.31, P=0.0003) from the first to the second time period. There were no significant changes between the time periods in death from cancer, infection, other or unknown. From the first to the second 8-year interval, the prevalence of cancer increased by 35% (P=0.0002) while the cancer incidence was stable.
CONCLUSIONS: In Danish patients with ADPKD and ESRD, there was a significant reduction in cardiovascular and cerebrovascular deaths from 1993 to 2008. The prevalence of cancer increased without significant change in cancer incidence or deaths from cancer.

Entities:  

Mesh:

Year:  2011        PMID: 21873624     DOI: 10.1093/ndt/gfr467

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  26 in total

1.  Blood pressure in early autosomal dominant polycystic kidney disease.

Authors:  Robert W Schrier; Kaleab Z Abebe; Ronald D Perrone; Vicente E Torres; William E Braun; Theodore I Steinman; Franz T Winklhofer; Godela Brosnahan; Peter G Czarnecki; Marie C Hogan; Dana C Miskulin; Frederic F Rahbari-Oskoui; Jared J Grantham; Peter C Harris; Michael F Flessner; Kyongtae T Bae; Charity G Moore; Arlene B Chapman
Journal:  N Engl J Med       Date:  2014-11-15       Impact factor: 91.245

Review 2.  The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.

Authors:  Tamina Seeger-Nukpezah; Daniel M Geynisman; Anna S Nikonova; Thomas Benzing; Erica A Golemis
Journal:  Nat Rev Nephrol       Date:  2015-04-14       Impact factor: 28.314

Review 3.  An approach to cystic kidney diseases: the clinician's view.

Authors:  Christine E Kurschat; Roman-Ulrich Müller; Mareike Franke; David Maintz; Bernhard Schermer; Thomas Benzing
Journal:  Nat Rev Nephrol       Date:  2014-09-30       Impact factor: 28.314

4.  Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Arlene B Chapman; Olivier Devuyst; Kai-Uwe Eckardt; Ron T Gansevoort; Tess Harris; Shigeo Horie; Bertram L Kasiske; Dwight Odland; York Pei; Ronald D Perrone; Yves Pirson; Robert W Schrier; Roser Torra; Vicente E Torres; Terry Watnick; David C Wheeler
Journal:  Kidney Int       Date:  2015-03-18       Impact factor: 10.612

5.  Liver involvement in early autosomal-dominant polycystic kidney disease.

Authors:  Marie C Hogan; Kaleab Abebe; Vicente E Torres; Arlene B Chapman; Kyongtae T Bae; Cheng Tao; Hongliang Sun; Ronald D Perrone; Theodore I Steinman; William Braun; Franz T Winklhofer; Dana C Miskulin; Frederic Rahbari-Oskoui; Godela Brosnahan; Amirali Masoumi; Irina O Karpov; Susan Spillane; Michael Flessner; Charity G Moore; Robert W Schrier
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-09       Impact factor: 11.382

Review 6.  Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?

Authors:  Zeina Al-Mansour; Linda Pang; Venu Bathini
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

7.  Urinary angiotensinogen level is associated with potassium homeostasis and clinical outcome in patients with polycystic kidney disease: a prospective cohort study.

Authors:  Hyoungnae Kim; Seohyun Park; Jong Hyun Jhee; Hae-Ryong Yun; Jung Tak Park; Seung Hyeok Han; Joongyub Lee; Soo Wan Kim; Yeong Hoon Kim; Yun Kyu Oh; Shin-Wook Kang; Kyu Hun Choi; Tae-Hyun Yoo
Journal:  BMC Nephrol       Date:  2019-03-25       Impact factor: 2.388

Review 8.  Current management of autosomal dominant polycystic kidney disease.

Authors:  Jacob A Akoh
Journal:  World J Nephrol       Date:  2015-09-06

9.  Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.

Authors:  Imed Helal; Kim McFann; Berenice Reed; Xiang-Dong Yan; Robert W Schrier; Godela M Fick-Brosnahan
Journal:  Nephrol Dial Transplant       Date:  2012-12-04       Impact factor: 5.992

10.  Polycystic kidney disease: Progression of polycystic kidney disease--a lack of progress?

Authors:  Stephen McDonald; Gopala Rangan
Journal:  Nat Rev Nephrol       Date:  2014-08-05       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.